AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06668025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MxA feedback
Description: MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.
Study NCT06668025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up at Day 30
Description: A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
Study NCT06668025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up at Day 30
Description: A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
Study NCT04940624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat mini-tablets or tablets.
Study NCT04940624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soticlestat placebo-matching mini-tablets or tablets.
Study NCT06669611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab combined GP chemotherapy
Description: Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.
Study NCT06669611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined TPC chemotherapy
Description: Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
Study NCT05215197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intracochlear platelet rich fibrin administration
Description: intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
Study NCT06677502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.
Study NCT06677502 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution - IV
Description: Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.
Study NCT06682416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In the context of epidural analgesia, the temperature of the local anesthetic solution is elevated to 37°C utilizing a blood transfusion and infusion warmer.
Description: For the observation group, after reactivating the analgesic pump's exhaust procedure to clear the air from the tubing, the output tubing of the analgesic pump is first connected to the epidural catheter. Following this, a blood transfusion and infusion warmer (manufactured by Barkey GmbH \& Co. KG., Germany, model S-line, with the national medical device registration number 20182450063) is used to preheat the output tubing of the analgesic pump until it reaches the predetermined temperature of 37°C.~For the control group, after reactivating the analgesic pump's exhaust procedure to remove air from the tubing, the output tubing of the analgesic pump is connected to the epidural catheter without preheating the output tubing using a blood transfusion and infusion warmer, maintaining room temperature (23°C).
Study NCT06690983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-S16/T807
Description: Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
Study NCT06691685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESO-T01 Injection
Description: ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
Study NCT04795245 — intervention group
Intervention type: DRUG
Intervention: afatinib
Description: afatinib
Study NCT06320860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney Stone Retrieval
Description: Using FlexStone Basket aimability to retrieve kidney stones
Study NCT05613426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Description: Very early use of Rosuvastatin before primary PCI in anterior STEMI
Study NCT05613426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20 mg
Description: Very early use of Rosuvastatin before primary PCI in anterior STEMI
Study NCT05613426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
Description: Very early use of Evolocumab before primary PCI in anterior STEMI
Study NCT04817969 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Biomet Persona Ti-Nidium Total Knee System
Description: Primary Knee Total Arthroplasty
Study NCT05303194 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Priorities Care (PPC) Approach
Description: First, identify patient priorities, and second align care received with those priorities.
Study NCT05303194 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted PPC
Description: First, identify patient priorities, and second align care received with those priorities.
Study NCT04996316 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Health record reviewed
Study NCT04996316 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participate in interview
Study NCT04996316 — intervention group
Intervention type: OTHER
Intervention: Media Intervention
Description: Use MammoScreen
Study NCT04996316 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT04996316 — intervention group
Intervention type: OTHER
Intervention: Training and Education
Description: Undergo training
Study NCT04866017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously every three weeks
Study NCT04866017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
Study NCT04866017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: 900 milligrams (mg) intravenously every three weeks
Study NCT04866017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology.
Study NCT04866017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
Study NCT06695897 — intervention group
Intervention type: DRUG
Intervention: Dupilumab
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study NCT06696300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Physiotherapy Group
Description: Classical physiotherapy group (CF) will be treated face to face for 30 sessions in total, 3 days a week, 10 weeks. Hotpack, Ultrasound, TENS and Basic Exercises will be applied to the CF group. Hotpack will be applied superficially to the lumbar region for 15 minutes. Ultrasound 1MHz- 1.5 Wt/cm2 will be applied to the lumbar region. TENS 50 Hz will be applied for 15 minutes, leaving the painful area in the middle. Basic exercises will be applied as 8-12 repetitions, 2 sets. The number of repetitions and sets will be increased as the tolerance of the patients increases.~Pelvic tilt exercises Supine hip flexor stretch Supine lumbar extensor stretch Crunches Cat-Camel Exercises
Study NCT06696300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Physiotherapy Group
Description: Classical physiotherapy group (CF) will be treated face to face for 30 sessions in total, 3 days a week, 10 weeks. Hotpack, Ultrasound, TENS and Basic Exercises will be applied to the CF group. Hotpack will be applied superficially to the lumbar region for 15 minutes. Ultrasound 1MHz- 1.5 Wt/cm2 will be applied to the lumbar region. TENS 50 Hz will be applied for 15 minutes, leaving the painful area in the middle. Basic exercises will be applied as 8-12 repetitions, 2 sets. The number of repetitions and sets will be increased as the tolerance of the patients increases.~Pelvic tilt exercises Supine hip flexor stretch Supine lumbar extensor stretch Crunches Cat-Camel Exercises
Study NCT06696300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foundation Inspiratory Muscle Training in Addition to Classical Physiotherapy
Description: In addition to Classical Physiotherapy, Foundation Inspiratory Muscle Training (IKE) will be treated face to face for 30 sessions, 3 days a week, 10 weeks. On other days, IKE will be applied at home for 15 minutes in the morning and evening for a total of 30 minutes and will be followed up with a diary. IKE will be applied with a device that can load with threshold pressure. The IKE group will continue the exercise program for 10 weeks. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be asked. As tolerance increases, the consecutive respiratory cycle will be increased. The intensity will be adjusted by taking weekly MIP measurements. Daily monitoring forms will be created for each participant to ensure exercise follow-up.
Study NCT06696300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training Group in Addition to Classical Physiotherapy
Description: Functional Inspiratory Muscle Training Group will receive functional inspiratory muscle training in addition to classical physiotherapy, 3 days a week, 10 weeks, 30 sessions in total, face-to-face treatment. On other days, foundation-ICE will be applied at home for 15 minutes in the morning and evening, for a total of 30 minutes, and will be followed with a diary. The same protocol will be applied with the foundation IKE group for teaching the respiratory cycle in the first 4 weeks, and resisted breathing will be worked simultaneously with the exercises in Table 2 in the last 6 weeks. The exercise program will be continued for a total of 10 weeks, including F-ICE, foundation IKE for the first 4 weeks, and F-ICE for 6 weeks thereafter. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be requested. As tolerance increases, the number of consecutive respiratory cycles will be increase
Study NCT06701357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR-CHOP+PD1 inhibitor
Description: Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； PD1 200mg D1
Study NCT06701357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR-CHOP + Orelabrutinib
Description: Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Orelabrutinib 150mg/qd D1-21
Study NCT06701357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR-CHOP + decitabine
Description: Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Decitabine 10mg/m2 D-5 - -1
Study NCT06720662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent-ethyl ester capsules
Description: Icosapent-ethyl ester (4.0 g of EPA) taken twice a day (2.0 g/day x 2) for six months.
Study NCT06720662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil Control
Description: Corn oil twice a day (2.0 g/day x 2) for six months.
Study NCT06724757 — intervention group
Intervention type: OTHER
Intervention: Health questionnaire
Description: The intervention involves the completion and analysis of an online questionnaire designed to assess the health (mental, physical, social) of caregivers aged 50 and over in Quebec. This assessment is based on a combination of questionnaires (CARE, 4-item Zarit scale, 4-item GDS, 3-item UCLA loneliness scale, etc.).
Study NCT06733181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REMINDER intervention
Description: The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.
Study NCT06720974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AquaReBal
Description: The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task.
Study NCT06720974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based RBT
Description: The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task.
Study NCT06732765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Description: Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes
Study NCT06732765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Traditional physical therapy program in form of stretching, strengthening and postural correction exercises
Study NCT06735079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL1017 (esmethadone HCI) (active drug)
Description: REL-1017 is an investigational drug administered as an oral tablet, once daily. The dosing regimen includes a 75 mg dose on Day 1 (three tablets) in the clinic, followed by 25 mg daily (one tablet) at home from Day 2 to Day 28, with regular safety, efficacy, and tolerability assessments REL-1017 (esmethadone HCl) is under investigation as a novel NMDAR antagonist. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression. REL-1017 also lacks dissociative effects seen with more potent NMDAR antagonists such as ketamine. Finally, REL-1017 does not appear to have metabolic or neurological side effects.
Study NCT06735079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD).
Study NCT06735365 — intervention group
Intervention type: OTHER
Intervention: CRRT
Description: Hemodiafiltration
Study NCT06742814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Stress ball: It is a ball with moderate hardness and softness, about 6 cm, which can be held and pressed by hand.
Study NCT06747780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: A digital booklet, text messages for two weeks, and two family-based activity boosters
Study NCT06747780 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control (Usual care)
Description: Control only
Study NCT06742203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Milk-Derived EVs
Description: WPMDE1 - Whey Protein Milk-Derived EVs, is a white powder obtained by filtration, concentration, and dehydrating whey solution, with the addition of sweeteners and flavorings to balance the taste. The WPMDE1 contains a known concentration of EVs (also known as milk exosomes).
Study NCT06750627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Erector Spinae Plane Block
Description: Catheter are placed between the erector spinae muscle and the transversus processus with ultrasound guidance, blocking the dorsal and ventral ramus from the thorax and abdominal spinal nerves, at the level of T5. Local anesthesia is injected. Drugs used are Bupivacaine 0.25% with volume of 25 ml.
Study NCT06750627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Intravenous Analgesia
Description: Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)
Study NCT06749067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Practices
Description: Experiment 1 Group Intervention: In the first session preparation session; face-to-face meeting with the women in the experimental group and then general information about the definition, purpose and applications of the mindfulness-based practice will be given, and the lack of information about the practice, if any, will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Awareness Practice, women will be focused on the moment with a 3-minute breathing exercise and then continue with the raisin exercise.